+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Leber Congenital Amaurosis Pipeline Analysis and Outlook, 2019

  • ID: 4772557
  • Report
  • 63 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Editas Medicine Inc
  • MeiraGTx Holdings Plc
  • Novelion Therapeutics Inc
  • Ocugen Inc
  • Ophthotech Corp
  • MORE
Leber Congenital Amaurosis pipeline

Leber Congenital Amaurosis pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Leber Congenital Amaurosis R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Leber Congenital Amaurosis report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Leber Congenital Amaurosis as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Leber Congenital Amaurosis with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Leber Congenital Amaurosis pipeline Profiled in detail

Key players actively participating in Leber Congenital Amaurosis pipeline are profiled along with their R&D progress in Leber Congenital Amaurosis treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Leber Congenital Amaurosis pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Leber Congenital Amaurosis treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Leber Congenital Amaurosis pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Leber Congenital Amaurosis pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Leber Congenital Amaurosis pipeline study
  • All recent news and developments related to Leber Congenital Amaurosis drugs are provided
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Editas Medicine Inc
  • MeiraGTx Holdings Plc
  • Novelion Therapeutics Inc
  • Ocugen Inc
  • Ophthotech Corp
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Leber Congenital Amaurosis Disease Overview

3. Leber Congenital Amaurosis Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Leber Congenital Amaurosis Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Leber Congenital Amaurosis Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Leber Congenital Amaurosis companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Leber Congenital Amaurosis Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Allergan Plc
  • Editas Medicine Inc
  • MeiraGTx Holdings Plc
  • Novelion Therapeutics Inc
  • Ocugen Inc
  • Ophthotech Corp
  • Oxford BioMedica Plc
  • ProQR Therapeutics NV
  • Spark Therapeutics Inc
  • Wave Life Sciences Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4772557
Adroll
adroll